Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective study.

JGH Open · 2024 · PMC10986296 · PMID 38572327

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

marginally significantP = 0.05actually significant

IRI and HOMA‐IR decreased from baseline to Week 48, although these decreases were marginally significant ( P = 0.05 and 0.07, respectively).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.